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Background and purpose: Reported associations between risk of radiation-induced normal tissue injury
and single nucleotide polymorphisms (SNPs) in TGFB1, encoding the pro-ﬁbrotic cytokine transforming
growth factor-beta 1 (TGF-b1), remain controversial. To overcome publication bias, the international
Radiogenomics Consortium collected and analysed individual patient level data from both published
and unpublished studies.
Materials and methods: TGFB1 SNP rs1800469 c.-1347T>C (previously known as C-509T) genotype, treat-
ment-related data, and clinically-assessed ﬁbrosis (measured at least 2 years after therapy) were avail-
able in 2782 participants from 11 cohorts. All received adjuvant breast radiotherapy. Associations
between late ﬁbrosis or overall toxicity, reported by STAT (Standardised Total Average Toxicity) score,
and rs1800469 genotype were assessed.
Results: No statistically signiﬁcant associations between either ﬁbrosis or overall toxicity and rs1800469
genotype were observed with univariate or multivariate regression analysis. The multivariate odds ratio
(OR), obtained from meta-analysis, for an increase in late ﬁbrosis grade with each additional rare allele of
rs1800469 was 0.98 (95% Conﬁdence Interval (CI) 0.85–1.11). This CI is sufﬁciently narrow to rule out any
clinically relevant effect on toxicity risk in carriers vs. non-carriers with a high probability.
Conclusion: This meta-analysis has not conﬁrmed previous reports of association between ﬁbrosis or
overall toxicity and rs1800469 genotype in breast cancer patients. It has demonstrated successful collab-
oration within the Radiogenomics Consortium.
 2012 Elsevier Ireland Ltd.Open access under CC BY-NC-ND license.
Radiotherapy and Oncology 105 (2012) 289–295During the last decade, a number of studies reported associa-
tions between risk of radiation therapy related normal tissue injury
and speciﬁc genetic variants [1–3]. Some of the most frequently
studied were single nucleotide polymorphisms (SNPs) in TGFB1,
which encodes transforming growth factor-beta 1 (TGF-b1).
TGF-b1 is a pro-ﬁbrotic cytokine, which stimulates differentia-
tion of ﬁbroblasts and production of extracellular matrix and
inhibits epithelial repair. It is strongly implicated in the atrophic-Cambridge, Department of
spital NHS Foundation Trust,
rnett).
er CC BY-NC-ND license.ﬁbrogenic response pathway that is a main component of normal
tissue injury after radiation therapy. The early phase of ﬁbrogene-
sis, after irradiation, may be considered as a wound-healing re-
sponse with up-regulation of pro-inﬂammatory cytokines, such
as TGF-b1 [4]. Endothelial cell killing leading to vascular damage
and macrophage activation both contribute to tissue hypoxia,
which in turn perpetuates ﬁbrosis. The role of TGF-b1 in the radi-
ation response may be multi-factorial – related to development of
ﬁbrosis, extracellular signalling, induction of apoptosis and inhibi-
tion of proliferation in response to DNA damage [4].
TGF-b1 has been implicated in the development of radiation-re-
lated ﬁbrosis in lung cancer patients. Some, but not all studies, re-
ported a correlation between elevated serum TGF-b1 levels and
increased ﬁbrosis after cancer radiotherapy [5]. The hitherto
290 Meta-analysis SNP TGF betalargest study on SNPs in TGFB1 (with 778 participants) found no
association with late radiotherapy toxicity [6]. In an accompanying
meta-analysis of all published studies on late effects, where odds-
ratios were reported or could be calculated, for the TGFB1 SNP
c.-1347T>C (previously known as C-509T), rs1800469 [2], odds ra-
tios of about 1.5 were reported with conﬁdence intervals just
above one. However, the possibility of publication bias was noted
as the distribution of reported associations was characterised by
small studies with high odds ratios, larger studies clustering
around the ‘line of no effect’, and a relative absence of small studies
reporting an inverse association.
The SNPs most frequently studied in TGFB1 are rs1800469
c.-1347T>C and rs1800470 (formerly rs1982073) c.29C>T (known
as T+29C) encoding Leu10Pro. SNP rs1800469 is in the promoter
region of TGFB1 but is not within any putative promoter regulatory
elements. SNP rs1800470 is in the signal peptide. The two SNPs
have been reported to act by altering the rate of secretion of
TGF-b1 and hence the circulating levels of mature protein. How-
ever, not all studies have demonstrated such a relationship [7] –
the presence, in the circulation, of both latent and activated forms
may complicate the interpretation of studies on circulating levels.
In an attempt to weigh the evidence from multiple studies and
overcome problems of publication bias, the international Radioge-
nomics Consortium [8] collected data from both published and
unpublished studies on SNPs in TGFB1 and radiation-induced nor-
mal tissue injury. In contrast to the majority of previous studies,
multivariate analysis, adjusting for patient and treatment variables
(covariates) associated with the risk of normal tissue injury, was
possible.Materials and methods
Patient data
Genotype of SNPs in TGFB1 and late toxicity data on 5555 pa-
tients from 21 different cohorts were collected from members of
the international Radiogenomics Consortium, including 3257 pa-
tients with breast cancer, 78 with cervical cancer, and 2220 with
prostate cancer (Table 1 and Supplementary Fig. 1). The current
analysis includes data from the breast cancer patients. Data from
patients with other tumour types will be investigated in subse-
quent analysis. In addition, data on patient- and treatment-related
factors were also collected from each cohort. Patient-related fac-
tors included age, smoking status, body mass index (BMI), breast
volume and the presence of co-morbidity such as diabetes mellitus
and hypertension. Treatment-related factors included total dose,
number of fractions, use of a radiotherapy boost, chemotherapy,
hormone-therapy, acute toxicity, post-operative infection and sur-
gical cosmesis. Due to the retrospective nature of our meta-analy-
sis not all covariates were available in all studies.Genotype data
Amongst the 20 cohorts included in this meta-analysis, the
SNPs most frequently studied in TGFB1 were rs1800469
c.-1347T>C (previously known as C-509T) and rs1800470 (formerly
rs1982073) c.29C>T (known as T+29C) encoding Leu10Pro. The
two SNPs are in strong linkage disequilibrium (LD) with each other
such that the minor T allele of c.-1347T>C and the minor C allele of
c.29C>T, encoding proline Pro10, tend to be inherited together. An
association was therefore sought between c.-1347T>C (rs1800469)
and the development of late radiotherapy toxicity. Table 1 shows
the genotyping platforms used in each cohort as well as selected
study characteristics. Supplementary Table 1 gives the distribution
of genotypes in each study and the minor allele frequency (MAF).In all studies, the genotype distributions did not differ from those
expected under Hardy Weinberg Equilibrium.Toxicity data
The toxicity endpoints recorded in each study are listed in Sup-
plementary Table 2. Some endpoints were graded using identical
scaling systems, whereas others used slightly different scoring
scales. Some studies reported the same endpoint at multiple time
points after therapy. For each of the breast patients, the endpoint
was selected which was judged to reﬂect breast ﬁbrosis most clo-
sely. As late toxicity can progress up to 10 years following radio-
therapy, where toxicity was recorded longitudinally, data from
the latest time point available were used. The incidence ofPgrade
2 late ﬁbrosis ranged from 1.3% to 56.1% among the studies and the
incidence across all studies was 25.2%.
The primary investigation was a univariate analysis of ﬁbrosis.
A Z-score was obtained for an individual patient (k) for the ﬁbrosis
endpoint for which that patient had a valid (non-missing) score, sk.
Zk ¼ ðsk MeanÞ=Standard Deviation
where Mean and Standard Deviation are taken over all cases in the
study population where ﬁbrosis data were available. Converting
individual toxicity scores to Z-scores eliminates the problem of
grades for one toxicity item not being directly comparable with
grades for another item. Z-scores deﬁne, for a particular endpoint,
whether a patient’s score is high or low relative to the distribution
of the scores of other patients in the population.
In addition, a secondary analysis of overall toxicity, reported by
the Standardised Total Average Toxicity (STAT) score [9], and geno-
type was performed. To obtain a STAT score for an individual pa-
tient (k), a standardised Z-score, Zk,i, is derived for each toxicity
endpoint (i) for which that patient has a valid (non-missing) score,
sk,i:
Zk;i ¼ ðsk;i MeaniÞ=Standard Deviationi
The STAT score for patient k, STATk, is simply the average of all non-
missing Z scores for that patient:
STATk ¼ mean Zk;i:Statistical analysis
Stata version 11.0 was used. Univariate analysis (UVA) was ini-
tially performed to look for an association between genotype at
rs1800469 and either ﬁbrosis or overall toxicity using the non-
parametric Spearman’s rank correlation coefﬁcient. UVA was also
performed on each cohort to determine the non-genetic factors
that inﬂuenced both ﬁbrosis and overall toxicity. Spearman’s rank
correlation coefﬁcient was used to test for associations between
ﬁbrosis or STAT scores and continuous covariates. The Mann–
Whitney two-sample statistic was used for binary covariates.
In order to quantify the prescribed radiation dose, and to ac-
count for differences in dose per fraction used in the participating
cohorts, the equivalent dose in 2 Gy fractions was calculated in
each patient using the formula:
EQD2a=b ¼ D  ððdþ a=bÞ=ð2þ a=bÞÞ;
where D = total dose, d = dose per fraction and the a/b ratio was as-
sumed to be 3.4 Gy, which was the value estimated for late change
in breast appearance (photographic) in the meta-analysis of START
trial A and the pilot RMH/GOC trial [10].
In addition, ordinal logistic regression was used to look for an
association between late ﬁbrosis and genotype. This was consid-
ered appropriate as late ﬁbrosis was scored using a graded scale
in all studies. No numeric relationship is assumed between these
Table 1
The cohorts and covariates included in the meta-analysis of genotype at SNP rs1800469 and the presence of late ﬁbrosis after radiotherapy to the breast.
Trial n Genotyping
platform
Fibrosis
endpoint
Covariates included
for ﬁbrosis residual
Endpoints in
STAT
Covariates included
for STAT residual
Length of
follow-up
(years)
Refs.
RAPPER 1010 Fluidigm Breast
shrinkage
(photos)
Age
Breast volume
Chemotherapy
Boost
Breast
shrinkage
(photos)
Telangiectasia
Oedema
Pigmentation
Pain
Oversensitivity
Acute toxicity week
3
Boost
Smoker status
DM
Breast volume
Actual volume 107%
Post-op infection
Surgical cosmesis
2 [12]
LeND wide
Local excision
493 SNPlex LS ﬁbrosis Age
Chemotherapy
Boost
EQD2 Gy
LS pain
LS ﬁbrosis
LS
telangiectasia
LS oedema
LS atrophy
Boost
Smoker
DM
Chemotherapy
Hypertension
EQD2 Gy
1.5–7 [14,15]
MARIERAD study 389 MassArray iPlex RTOG ﬁbrosis Age
BMI
Boost
EQD2 Gy
Telangiectasia
Fibrosis in
operation site
Boost dose
Smoker
DM
BMI
EQD2 Gy
>5 [15]
Post-mastectomy DBCG2 234 ABI TaqMan LS Fibrosis Age
EQD2 Gy
Chemotherapy
(concurrent)
Variable [16]
RACE 190 ABI 3730
automated
sequencer
Breast
shrinkage
(photos)
Age
Boost
Estimated breast
volume
Chemotherapy
EQD2 Gy
Breast
shrinkage
(photos)
Telangiectasia
Oedema
Breast
symptoms
(QoL)
Boost
Chemotherapy
Estimated breast
volume
Surgical deﬁcit
EQD2 Gy
2 & 5 [17]
LeND mastectomy 134 SNPlex LS ﬁbrosis Age
Chemotherapy
EQD2 Gy
LS pain
LS ﬁbrosis
LS
telangiectasia
Smoker
DM
Chemotherapy
EQD2 Gy
1.5–7 [14,15]
Gene-PARE 92 DHPLC RTOG
palpation
Age
EQD2 Gy
RTOG visual
exam
RTOG
palpation
Acute toxicity week
5
Smoker
DM
EQD2 Gy
>2 [18]
TGFB prospective study in
Sant Pau Hospital,
Barcelona
78 Sanger
sequencing
RTOG
subcutaneous
tissue
Age
BMI
Chemotherapy
Boost
EQD2 Gy
RTOG skin
RTOG
subcutaneous
tissue
Acute toxicity
Boost Smoker
DM
Chemotherapy
BMI
Total dose
Surgical cosmesis
2
Hamburg
Fibrosis breast
69 RFLP LS ﬁbrosis Age
Chemotherapy
EQD2 Gy
2 [7,21]
Post-mastectomy DBCG1 41 ABI SNaPshot LS ﬁbrosis Age
EQD2 Gy
Variable [19]
Post-lumpectomy pre-START
trial
52 ABI SNaPshot/
Taqman
Induration Age
Breast size
Chemotherapy
Boost
EQD2 Gy
1–5 [20]
Abbreviations: ABI, Applied Biosystems™; RFLP, Restriction Fragment Length Polymorphism; DHPLC, Denaturing High-Performance Liquid Chromatography; LS, LENT-SOM
(Late effects on Normal Tissues-Subjective Objective Management); RTOG, Radiation Therapy Oncology Group; DM, diabetes mellitus; BMI, body mass index; QoL, Quality of
Life; Post-op, post-operative; EQD2 Gy, equivalent dose in 2 Gy fractions; RAPPER, Radiogenomics: Assessment of Polymorphisms for Predicting the Effects of Radiotherapy;
LeND, Leicester Nottingham Derby; MARIERAD, Mammakarzinom-Risikofaktoren-Erhebung’’ – Mammary Carcinoma Risk Factor Investigation Radiotherapy; DBCG, Danish
Breast Cancer Group; RACE, Radiation Complications and Epidemiology; Gene-PARE, genetic predictors of Adverse Radiotherapy Effects; START, Standardisation of Breast
Radiotherapy.
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reactions. Patients are assumed to have a decreasing risk of devel-
oping a speciﬁc grade of reaction when going from rare allele
homozygous to heterozygous and to common allele homozygous.This form of regression effectively looks for a trend both down
and across a table of toxicity score against genotype and has great-
er power than simple dichotomization of the toxicity endpoints,
e.g. <grade 2 or Pgrade 2. Univariate and multivariate analyses
292 Meta-analysis SNP TGF betawere performed, including factors that were associated with ﬁbro-
sis with P-value <0.1 in each data set (Supplementary Table 3). The
analyses were also repeated including any factors that were asso-
ciated with ﬁbrosis in the largest dataset with P-value <0.1. The
inclusion of these additional factors did not signiﬁcantly change
the results of the analysis (data not shown).
The resulting univariate and multivariate odds ratios for each
study were meta-analysed and Forest plots created, using the Der-
Simonian–Laird random-effects model. This model assumes heter-
ogeneity between the studies; i.e., it assumes that the true effect
can be different for each study. It is assumed that the individual-
study true effects are distributed around an overall true effect,
but the model makes no assumptions about the form of the distri-
bution of either the within-study or the between-studies effects.
Meta-analysis was also repeated with a ﬁxed effect model which
assumes no heterogeneity between studies.
Multivariate linear regression of STAT score with genotype at
rs1800469 was then performed on each cohort, including covari-
ates associated with overall toxicity on univariate analysis of that
cohort with P-value <0.1 or of the largest cohort in the data set.
Linear regression was considered appropriate as STAT scores follow
an approximately normal distribution. Supplementary Table 3
shows the results of univariate analysis of association between
covariates and overall late toxicity for the 11 studies. After multi-
variate analysis (MVA), residuals were calculated for each patient,
for the STAT score (R-STAT), to quantify the overall toxicity not ex-Fig. 1. Forest plot of odds ratios obtained from multivariate ordinal logistic regression
corresponding conﬁdence intervals.plained by available patient and treatment related factors (Table 1)
[11]. A residual is the difference between the observed and the esti-
mated toxicity score. Patients with residuals of zero have toxicity
entirely accounted for by these factors. Patients with negative or
positive residuals have less or greater toxicity respectively than
is explained by known factors. Residuals were used in the analysis
as clinical data were available in some patients from the cohorts
who did not have genotyped data. This meant that the clinical fac-
tors that inﬂuence toxicity could be determined in all patients to
maximise power and the resulting factors used in the calculation
of residuals in patients for whom genetic data were available.Results
The minimally required data: SNP rs1800469 genotype, treat-
ment variables, and clinically-assessed ﬁbrosis (measured 2 years
or later after therapy) were available in 2782 participants who
had received adjuvant radiotherapy to the breast, from 11 cohorts.
Supplementary Fig. 1 shows the CONSORT diagram for this meta-
analysis. Table 1 shows the number of patients included from each
cohort, the endpoints used to score ﬁbrosis and calculate overall
toxicity reported by the STAT score as well as the covariates in-
cluded in multivariate analysis.
On initial univariate analysis there was no evidence of associa-
tion between rs1800469 genotype and either ﬁbrosis or overallof ﬁbrosis by genotype for all 11 cohorts included in the meta-analysis, with the
G.C. Barnett et al. / Radiotherapy and Oncology 105 (2012) 289–295 293toxicity. Spearman’s correlation coefﬁcient of Z scores for ﬁbrosis
and genotype was 0.02 (P = 0.38) and the correlation between
overall toxicity and genotype was 0.005 (P = 0.80). Meta-analysis
of the univariate odds ratios obtained from ordinal logistic regres-
sion in all data sets gave an OR = 1.015 (95% CI 0.89, 1.14), with no
signiﬁcant evidence of heterogeneity in this effect size between
studies (P = 0.67).
Multivariate analysis was next performed, adjusting for all vari-
ables found to be associated with late toxicity. Fig. 1 shows the For-
est plot of odds ratios obtained from multivariate ordinal logistic
regression of ﬁbrosis by genotype for all 11 cohorts included in
the meta-analysis, with the corresponding conﬁdence intervals.
Smaller trials have larger conﬁdence intervals, reﬂecting the de-Table 2
The univariate and multivariate odds ratios (OR) and standard errors (SE) obtained from o
Study n (UVA) OR (UVA)
RAPPER 786 0.99
LeND WLE 480 1.13
MARIE 389 1.24
Post-mastectomy DBCG 2 234 1.00
RACE 161 0.75
LeND mastectomy 132 1.45
Gene-PARE 92 1.24
Sant Pau 78 0.67
Hamburg 69 1.94
Post-mastectomy DBCG 1 41 1.19
Pre-START trial 52 1.13
UVA, univariate analysis; MVA, multivariate analysis; OR, odds ratio; SE, standard error;
Radiotherapy; LeND, Leicester Nottingham Derby; MARIERAD, Mammakarzinom-Risikofa
DBCG, Danish Breast Cancer Group; RACE, Radiation Complications and Epidemiology;
sation of Breast Radiotherapy.
Fig. 2. Forest plot of the regression coefﬁcients for residuals of overall toxicity and geno
with the corresponding conﬁdence intervals.creased power to detect an association between genotype and
the development of late ﬁbrosis of the breast. The multivariate
OR obtained from meta-analysis, for an increase in late ﬁbrosis
grade with each additional rare allele of rs1800469 was 0.98
(95% CI 0.85–1.11). The corresponding 99% CI are 0.81–1.13. Thus,
the null hypothesis that the OR equals 1 could not be rejected, i.e.
there was no association between the SNP and risk of subcutane-
ous ﬁbrosis in breast cancer patients. Table 2 shows the univariate
and multivariate odds ratios and standard errors obtained for the
ordinal regression of ﬁbrosis against genotype at rs1800469. The
results of meta-analysis did not change when a ﬁxed-effect model
was used (data not shown).rdinal regression of ﬁbrosis against genotype at rs1800469.
SE (UVA) n (MVA) OR (MVA) SE (MVA)
0.11 773 1.00 0.12
0.17 480 1.12 0.16
0.21 389 1.16 0.20
0.17 234 0.80 0.16
0.18 145 0.81 0.21
0.72 132 1.38 0.67
0.45 92 1.24 0.45
0.32 78 0.56 0.30
0.72 69 1.94 0.72
0.49 41 2.05 1.00
0.41 52 1.11 0.41
RAPPER, Radiogenomics: Assessment of Polymorphisms for Predicting the Effects of
ktoren-Erhebung’’ – Mammary Carcinoma Risk Factor Investigation Radiotherapy;
Gene-PARE, Genetic Predictors of Adverse Radiotherapy Effects; START, Standardi-
type for each of the seven cohorts with more than one toxicity endpoint available,
294 Meta-analysis SNP TGF betaMultivariate linear regression of overall toxicity with genotype
at rs17800469 was performed to obtain residuals. The residuals
therefore quantify the toxicity not explained by available patient
and treatment related factors, i.e. they are the difference between
the observed and the estimated toxicity score. Fig. 2 shows the For-
est plot of the regression coefﬁcients for residuals of overall toxic-
ity and genotype for each of the seven cohorts with more than one
toxicity endpoint available, with the corresponding conﬁdence
intervals. Meta-analysis reveals that each additional rare allele of
rs1800469 corresponds to a 0.026 increase in STAT score (95% CI
0.074 to 0.126). Thus, the null hypothesis that this coefﬁcient
of regression equals 0 could not be rejected, i.e. there was no sig-
niﬁcant association between the SNP and overall toxicity in breast
cancer patients.Discussion
This meta-analysis did not conﬁrm previously reported associa-
tions between TGFB1 SNP c.-1347T>C (rs1800469) and increased
risk of radiation-induced ﬁbrosis in breast cancer patients. After
adjustment for covariates which inﬂuence the development of
radiation ﬁbrosis, this meta-analysis enables the exclusion of an
odds ratio >1.13 associated with the T allele, with >99% conﬁdence.
We can translate this into a conﬁdence interval for the increased
risk (around the overall average risk) of ﬁbrosis in carriers vs.
non-carriers. Assuming an incidence of Pgrade 2 ﬁbrosis of
25.2% after adjustment for covariates, we can exclude an incidence
ofPgrade 2 ﬁbrosis greater than 28.5% for carriers of the rare allele
of rs1800469 with >99% conﬁdence. Thus, the statistical power of
the present analysis is sufﬁcient to rule out a clinically relevant dif-
ference in risk of moderate/severe ﬁbrosis between carriers and
non-carriers of the rs1800469 SNP with a high probability.
This is the ﬁrst unbiased evaluation, with sufﬁcient statistical
power and adjustment for covariates, on a SNP that has been re-
ported to be associated with radiation-induced normal tissue in-
jury. The strengths of the current study include its large size, the
use of both published and unpublished data and the availability
of non-genetic factors that inﬂuence toxicity.
SNP rs1800469 is in the promoter region of TGFB1, but its effect
on secretion and hence circulating levels of the cytokine remains
unclear [7,22]. In addition the development of radiation ﬁbrosis,
a complex multi-factorial process, involving atrophy of normal tis-
sues and excess collagen deposition, involves complex interactions
between many proteins. Therefore it is possible that genetic varia-
tion in many proteins will inﬂuence the development of radiother-
apy toxicity in a complex fashion.
Radiotherapy toxicity is a complex phenotype involving a vari-
ety of different pathological mechanisms, and these different pro-
cesses lead to a variety of different clinical end-points. Despite a
recognised need for a standardised approach for reporting toxicity,
a variety of scoring systems are used and toxicity remains gener-
ally under-reported. In this meta-analysis, an attempt was made
to minimise these problems by studying a single clinical endpoint
(ﬁbrosis) in breast cancer patients. Patients from clinical trials or
dedicated radiogenomics studies were included. In each study
the toxicity endpoint selected was judged to reﬂect breast ﬁbrosis
most closely. Note, that in a meta-analysis all effect estimates are
within a speciﬁc study rather than between studies. Thus, it is not
necessary to assume consistency in grading and use of scales
across studies. It is also noteworthy that the toxicity scoring used
in most cases had face validity in the sense that factors known to
inﬂuence toxicity were found to have a signiﬁcant impact on the
toxicity scores. The current analysis corrects for total dose and
dose fractionation, which is one of the most important non-genetic
risk factors. However, due to the retrospective design of the analy-sis, it was not possible to include volume-related parameters.
Whenever possible, future prospective studies should aim to in-
clude sufﬁcient information on both dose and volume related
parameters. The more accurate the information included on the
non-genetic factors that inﬂuence late toxicity, the greater the
chance of determining the genetic factors that determine radio-
therapy toxicity. However, sample size is paramount. Most pub-
lished GWAS have shown that a large sample size, even if the
data are ‘‘noisy’’, is more effective for detecting associations than
a smaller sample size with very clean data.
The odds ratios and standard errors obtained fromUVA andMVA
of each data set were similar (Table 2). This means that in these
studies the adjustment for covariates did not signiﬁcantly alter
the magnitude of the effect size of genotype at rs1800469. This im-
plies that for SNPs that are not signiﬁcantly associated with radio-
therapy toxicity, i.e. true negative results, the adjustment for
covariates does not have an undue inﬂuence on the results. It could
be hypothesised that the effect of genotypemay be constant despite
increases in dose or the addition of other treatments, such as che-
motherapy. However, it is possible that for a SNP that is truly asso-
ciated with toxicity, adjustment for covariates would have a
signiﬁcant effect on the magnitude of the odds ratio. The relative
importance of the inclusion of non-genetic factors will be demon-
strated once univariate and multivariate analyses are performed
on SNPs that are found to be truly associated with late radiotherapy
toxicity.
The Radiogenomics Consortium was established in Manchester
in 2009 [8] to provide a collaborative link between the major
groups performing genotyping studies and existing cancer epide-
miology cohorts in radiogenomics. It provides a route for sharing
and developing expertise and quality assurance procedures; devel-
oping best practices for data collection; pooling data, addressing
methodological challenges associated with radiogenomics and car-
rying out large, sufﬁciently powered studies. This meta-analysis of
both published and unpublished studies demonstrates the Consor-
tium’s ability to achieve its collaborative goals and has successfully
overcome a publication bias problem.
Genome-wide association studies have highlighted the limita-
tions of our current understanding of the genetic basis of most
complex traits and diseases. Radiosensitivity is a complex pheno-
type and positive ﬁndings from candidate gene studies have
proved difﬁcult to replicate [12]. Several Stage 1 GWAS of radioge-
nomics are underway [13], the future meta-analysis of which
should identify true causative variants. The large amount of data
collected for this meta-analysis (Supplementary Fig. 1) highlight
the need for standardisation between studies of radiogenomics in
the Consortium.
In conclusion, this relatively large meta-analysis, found no clin-
ically relevant association between the frequently-studied candi-
date SNP rs1800469 in TGFB1 and the development of ﬁbrosis or
other late radiotherapy toxicity. The meta-analysis demonstrates
successful collaboration of groups included in the Radiogenomics
Consortium.Conﬂicts of interest statement
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